Giant Merck buddies up with little KalVista on lead drug, igniting stock with a $760M deal
Pharma giant Merck $MRK is buying into micro cap biotech player KalVista $KALV, bagging an option on a lead drug and outlining a rich potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
